The global esophageal cancer market is slated to grow with increase in the number of patients suffering from undiagnosed achalasia followed by noticeable R&D in this regard.
Innovative launches regarding medications to treat ovarian cancer are contributing to the revenue from esophageal cancer industry. Furthermore, researchers state that extensive lymphadenectomy is likely to improve survival in the node negative esophageal cancer.
The companies operating in the esophageal cancer market are working toward incorporating outcomes of trials implementing chemo before as well as surgery.
They are also exploring use of AI to provide personalized treatment strategies for esophageal cancer, along with synchronizing with the update that oligometastatic disease falls in the category of esophagogastric cancer.
The esophagus is a hollow, long tube running from throat to stomach. It helps in moving swallowed food from the back of the throat to stomach to enable digestion. Esophageal cancer means growth of cells in esophagus.
Research states that men are at a higher risk of esophageal cancer. The risk factors include smoking and alcoholism. The treatment often involves radiation, chemotherapy, or a combination of two. These days, immunotherapy, targeted therapy, and nanomaterials are also used.
Difficulty in swallowing, drastic weight loss, chest pain, burning or pressure, heartburn or worsening indigestion, and coughing or hoarseness are the symptoms of esophageal cancer.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
Achalasia means a primary esophageal motility disorder that is characterized by failure of lower esophageal sphincter (LES) and esophageal aperistalsis. Research states that family history of Allgrove syndrome drives the proliferation of esophageal cancer.
The symptoms of achalasia include chest pain, dysphagia, weight loss, regurgitation, and rare pulmonary complications. It is advisable to consult a doctor in case of an abrupt weight loss or chest pain, especially when there is no background to any of these.
Various awareness campaigns are being organized regarding the need to get checked for incidence of achalasia. This would help in achalasia not going unnoticed, which would, in turn, suggest healthcare personnel to take corrective measures before the achalasia takes the severe turn such as esophageal cancer.
Immune checkpoint inhibitors (ICIs), which include programmed cell death-1 antibodies, are revolutionizing esophageal cancer’s treatment paradigm. ICIs, post demonstration of promising efficacy with reasonable safety in various clinical trials, have reached a point from where they can be utilized in several stages of tumor in clinical settings. ICIs are likely to enhance prognosis in those suffering from esophageal cancer now as well as in future.
Use of nanomaterials as drug delivery systems or drugs have advantages such as adjustably specific targeting capability, higher drug capacity. They revolve around five aspects with regards to therapy of esophageal cancer.
In May 2024, Astellas Pharma Inc. announced that the U.S. FDA had acknowledged the resubmission of the company’s Biologics License Application (BLA) for zolbetuximab, one of the first-in-class investigational claudin (CLDN) 18.2-targeted monoclonal antibodies, as a first-line treatment for adults suffering from locally advanced metastatic or unreasonable human epidermal growth factor receptor (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2 positive.
Continual R&D activities pertaining to esophageal cancer treatment are thus expanding the esophageal cancer market size.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest esophageal cancer market insights, North America dominated the esophageal carcinoma landscape in 2023 and the status quo is expected to remain unchanged during the forecast period.
This is attributed to growing incidence of esophageal cancer in the U.S. For instance, as per the report published by American Cancer Society, close to 17,000 new esophageal cancer cases were diagnosed in the U.S. in 2019 alone.
Asia Pacific’s esophageal cancer market growth is ascribed to increase in the number of clinical trials pertaining to esophageal cancer therapeutics. For instance, evaluation of combination therapy with induction DCF (docetaxel plus cisplatin and 5-fluorouracil) and definitive chemo-radiotherapy for the locally advanced carcinoma of thoracic esophagus is underway.
The key participants in the esophageal cancer market are engaging in collaborations to strengthen their foothold. For instance, in March 2023, GSK plc, along with SCYNEXIS, Inc., bought the rights for commercializing Brexafemme worldwide. The U.S. FDA has approved these ibrexafungerp tablets for treating/preventing vulvovaginal candidiasis (VVC) in the U.S.
Bristol-Myers Squibb Company, Merck & Co., Inc., Eli Lilly and Company, AstraZeneca plc, F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Sanofi S.A., The Takeda Pharmaceutical Company Limited, and Bayer AG are some of the key players covered in the esophageal cancer market report.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 2.2 Bn |
| Market Forecast (Value) in 2034 | US$ 4.6 Bn |
| Growth Rate (CAGR) | 6.7% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 2.2 Bn in 2023
It is projected to grow at a CAGR of 6.7% from 2024 to 2034
Growing prevalence of undiagnosed achalasia and extensive R&D activities
Hospitals segment accounted for the largest share in 2023
North America was the dominant region in 2023
Bristol-Myers Squibb Company, Merck & Co., Inc., Eli Lilly and Company, AstraZeneca plc, F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, Sanofi S.A., The Takeda Pharmaceutical Company Limited, and Bayer AG
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Esophageal Cancer Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Esophageal Cancer Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product /Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Esophageal Cancer Market Analysis and Forecast, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Type, 2020-2034
6.3.1. Chemotherapy
6.3.2. Radiation Therapy
6.3.3. Targeted Therapy
6.3.4. Immunotherapy
6.3.5. Others
6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Esophageal Cancer Market Analysis and Forecast, by Stage of Cancer
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Stage of Cancer, 2020-2034
7.3.1. Early-stage Esophageal Cancer
7.3.2. Advanced Esophageal Cancer
7.4. Market Attractiveness Analysis, by Stage of Cancer
8. Global Esophageal Cancer Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2020-2034
8.3.1. Hospitals
8.3.2. Specialty Clinics
8.3.3. Cancer Treatment Centers
8.3.4. Ambulatory Surgical Centers
8.4. Market Attractiveness Analysis, by End-user
9. Global Esophageal Cancer Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2020-2034
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Esophageal Cancer Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment Type, 2020-2034
10.3.1. Chemotherapy
10.3.2. Radiation Therapy
10.3.3. Targeted Therapy
10.3.4. Immunotherapy
10.3.5. Others
10.4. Market Value Forecast, by Stage of Cancer, 2020-2034
10.4.1. Early-stage Esophageal Cancer
10.4.2. Advanced Esophageal Cancer
10.5. Market Value Forecast, by End-user, 2020-2034
10.5.1. Hospitals
10.5.2. Specialty Clinics
10.5.3. Cancer Treatment Centers
10.5.4. Ambulatory Surgical Centers
10.6. Market Value Forecast, by Country, 2020-2034
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Treatment Type
10.7.2. By Stage of Cancer
10.7.3. By End-user
10.7.4. By Country
11. Europe Esophageal Cancer Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment Type, 2020-2034
11.3.1. Chemotherapy
11.3.2. Radiation Therapy
11.3.3. Targeted Therapy
11.3.4. Immunotherapy
11.3.5. Others
11.4. Market Value Forecast, by Stage of Cancer, 2020-2034
11.4.1. Early-stage Esophageal Cancer
11.4.2. Advanced Esophageal Cancer
11.5. Market Value Forecast, by End-user, 2020-2034
11.5.1. Hospitals
11.5.2. Specialty Clinics
11.5.3. Cancer Treatment Centers
11.5.4. Ambulatory Surgical Centers
11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Treatment Type
11.7.2. By Stage of Cancer
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Esophageal Cancer Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment Type, 2020-2034
12.3.1. Chemotherapy
12.3.2. Radiation Therapy
12.3.3. Targeted Therapy
12.3.4. Immunotherapy
12.3.5. Others
12.4. Market Value Forecast, by Stage of Cancer, 2020-2034
12.4.1. Early-stage Esophageal Cancer
12.4.2. Advanced Esophageal Cancer
12.5. Market Value Forecast, by End-user, 2020-2034
12.5.1. Hospitals
12.5.2. Specialty Clinics
12.5.3. Cancer Treatment Centers
12.5.4. Ambulatory Surgical Centers
12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Treatment Type
12.7.2. By Stage of Cancer
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Esophageal Cancer Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Treatment Type, 2020-2034
13.3.1. Chemotherapy
13.3.2. Radiation Therapy
13.3.3. Targeted Therapy
13.3.4. Immunotherapy
13.3.5. Others
13.4. Market Value Forecast, by Stage of Cancer, 2020-2034
13.4.1. Early-stage Esophageal Cancer
13.4.2. Advanced Esophageal Cancer
13.5. Market Value Forecast, by End-user, 2020-2034
13.5.1. Hospitals
13.5.2. Specialty Clinics
13.5.3. Cancer Treatment Centers
13.5.4. Ambulatory Surgical Centers
13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Treatment Type
13.7.2. By Stage of Cancer
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Esophageal Cancer Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Treatment Type, 2020-2034
14.3.1. Chemotherapy
14.3.2. Radiation Therapy
14.3.3. Targeted Therapy
14.3.4. Immunotherapy
14.3.5. Others
14.4. Market Value Forecast, by Stage of Cancer, 2020-2034
14.4.1. Early-stage Esophageal Cancer
14.4.2. Advanced Esophageal Cancer
14.5. Market Value Forecast, by End-user, 2020-2034
14.5.1. Hospitals
14.5.2. Specialty Clinics
14.5.3. Cancer Treatment Centers
14.5.4. Ambulatory Surgical Centers
14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Treatment Type
14.7.2. By Stage of Cancer
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2023)
15.3. Company Profiles
15.3.1. Bristol-Myers Squibb Company
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Merck & Co., Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Eli Lilly and Company
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. AstraZeneca plc
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. F. Hoffmann-La Roche AG
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Pfizer Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Novartis AG
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Sanofi S.A.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. The Takeda Pharmaceutical Company Limited
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Bayer AG
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Esophageal Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 02: Global Esophageal Cancer Market Size (US$ Bn) Forecast, by Stage of Cancer, 2020-2034
Table 03: Global Esophageal Cancer Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 04: Global Esophageal Cancer Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 05: North America Esophageal Cancer Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 06: North America Esophageal Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 07: North America Esophageal Cancer Market Size (US$ Bn) Forecast, by Stage of Cancer, 2020-2034
Table 08: North America Esophageal Cancer Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 09: Europe Esophageal Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 10: Europe Esophageal Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 11: Europe Esophageal Cancer Market Size (US$ Bn) Forecast, by Stage of Cancer, 2020-2034
Table 12: Europe Esophageal Cancer Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 13: Asia Pacific Esophageal Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 14: Asia Pacific Esophageal Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 15: Asia Pacific Esophageal Cancer Market Size (US$ Bn) Forecast, by Stage of Cancer, 2020-2034
Table 16: Asia Pacific Esophageal Cancer Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 17: Latin America Esophageal Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 18: Latin America Esophageal Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 19: Latin America Esophageal Cancer Market Size (US$ Bn) Forecast, by Stage of Cancer, 2020-2034
Table 20: Latin America Esophageal Cancer Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 21: Middle East & Africa Esophageal Cancer Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Middle East & Africa Esophageal Cancer Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
Table 23: Middle East & Africa Esophageal Cancer Market Size (US$ Bn) Forecast, by Stage of Cancer, 2020-2034
Table 24: Middle East & Africa Esophageal Cancer Market Size (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Esophageal Cancer Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2034
Figure 02: Global Esophageal Cancer Market Revenue (US$ Bn), by Treatment Type, 2023
Figure 03: Global Esophageal Cancer Market Value Share, by Treatment Type, 2023
Figure 04: Global Esophageal Cancer Market Revenue (US$ Bn), by Stage of Cancer, 2023
Figure 05: Global Esophageal Cancer Market Value Share, by Stage of Cancer, 2023
Figure 06: Global Esophageal Cancer Market Revenue (US$ Bn), by End-user, 2023
Figure 07: Global Esophageal Cancer Market Value Share, by End-user, 2023
Figure 08: Global Esophageal Cancer Market Value Share, by Region, 2023
Figure 09: Global Esophageal Cancer Market Value (US$ Bn) Forecast, 2020-2034
Figure 10: Global Esophageal Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 11: Global Esophageal Cancer Market Attractiveness Analysis, by Region, 2024-2034
Figure 12: Global Esophageal Cancer Market Value Share Analysis, by Stage of Cancer, 2023 and 2034
Figure 13: Global Esophageal Cancer Market Attractiveness Analysis, by Stage of Cancer, 2024-2034
Figure 14: Global Esophageal Cancer Market Value Share Analysis, by End-user, 2023 and 2034
Figure 15: Global Esophageal Cancer Market Attractiveness Analysis, by End-user, 2024-2034
Figure 16: Global Esophageal Cancer Market Value Share Analysis, by Region, 2023 and 2034
Figure 17: Global Esophageal Cancer Market Attractiveness Analysis, by Region, 2024-2034
Figure 18: North America Esophageal Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 19: North America Esophageal Cancer Market Attractiveness Analysis, by Country, 2024-2034
Figure 20: North America Esophageal Cancer Market Value Share Analysis, by Country, 2023 and 2034
Figure 21: North America Esophageal Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 22: North America Esophageal Cancer Market Value Share Analysis, by Stage of Cancer, 2023 and 2034
Figure 23: North America Esophageal Cancer Market Value Share Analysis, by End-user, 2023 and 2034
Figure 24: North America Esophageal Cancer Market Attractiveness Analysis, by Region, 2024-2034
Figure 25: North America Esophageal Cancer Market Attractiveness Analysis, by Stage of Cancer, 2024-2034
Figure 26: North America Esophageal Cancer Market Attractiveness Analysis, by End-user, 2024-2034
Figure 27: Europe Esophageal Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 28: Europe Esophageal Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 29: Europe Esophageal Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 30: Europe Esophageal Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 31: Europe Esophageal Cancer Market Value Share Analysis, by Stage of Cancer, 2023 and 2034
Figure 32: Europe Esophageal Cancer Market Value Share Analysis, by End-user, 2023 and 2034
Figure 33: Europe Esophageal Cancer Market Attractiveness Analysis, by Region, 2024-2034
Figure 34: Europe Esophageal Cancer Market Attractiveness Analysis, by Stage of Cancer, 2024-2034
Figure 35: Europe Esophageal Cancer Market Attractiveness Analysis, by End-user, 2024-2034
Figure 36: Asia Pacific Esophageal Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 37: Asia Pacific Esophageal Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 38: Asia Pacific Esophageal Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 39: Asia Pacific Esophageal Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 40: Asia Pacific Esophageal Cancer Market Value Share Analysis, by Stage of Cancer, 2023 and 2034
Figure 41: Asia Pacific Esophageal Cancer Market Value Share Analysis, by End-user, 2023 and 2034
Figure 42: Asia Pacific Esophageal Cancer Market Attractiveness Analysis, by Region, 2024-2034
Figure 43: Asia Pacific Esophageal Cancer Market Attractiveness Analysis, by Stage of Cancer, 2024-2034
Figure 44: Asia Pacific Esophageal Cancer Market Attractiveness Analysis, by End-user, 2024-2034
Figure 45: Latin America Esophageal Cancer Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 46: Latin America Esophageal Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 47: Latin America Esophageal Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 48: Latin America Esophageal Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 49: Latin America Esophageal Cancer Market Value Share Analysis, by Stage of Cancer, 2023 and 2034
Figure 50: Latin America Esophageal Cancer Market Value Share Analysis, by End-user, 2023 and 2034
Figure 51: Latin America Esophageal Cancer Market Attractiveness Analysis, by Region, 2024-2034
Figure 52: Latin America Esophageal Cancer Market Attractiveness Analysis, by Stage of Cancer, 2024-2034
Figure 53: Latin America Esophageal Cancer Market Attractiveness Analysis, by End-user, 2024-2034
Figure 54: Middle East & Africa Esophageal Cancer Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 55: Middle East & Africa Esophageal Cancer Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 56: Middle East & Africa Esophageal Cancer Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 57: Middle East & Africa Esophageal Cancer Market Value Share Analysis, by Treatment Type, 2023 and 2034
Figure 58: Middle East & Africa Esophageal Cancer Market Value Share Analysis, by Stage of Cancer, 2023 and 2034
Figure 59: Middle East & Africa Esophageal Cancer Market Value Share Analysis, by End-user, 2023 and 2034
Figure 60: Middle East & Africa Esophageal Cancer Market Attractiveness Analysis, by Region, 2024-2034
Figure 61: Middle East & Africa Esophageal Cancer Market Attractiveness Analysis, by Stage of Cancer, 2024-2034
Figure 62: Middle East & Africa Esophageal Cancer Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Esophageal Cancer Market
